Merck (MRK) Other financing activities (2009 - 2026)

Merck (MRK) has reported Other financing activities for 18 consecutive years, with -$507.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 247.26% year-over-year to -$507.0 million in Q2 2026; TTM through Jun 2026 was -$275.0 million, a 1.79% increase from a year earlier, with the FY2025 full-year figure at -$131.0 million, up 64.78% from the prior year.
• Other financing activities was -$507.0 million for Q2 2026 at Merck, down from $157.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $556.0 million in Q4 2022 and troughed at -$507.0 million in Q2 2026.
• A 5-year average of -$44.3 million and a median of -$44.0 million in 2024 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities slumped 1300.0% in 2024 and surged 388.1% in 2025, its largest moves.
• Over 5 years, Other financing activities stood at $556.0 million in 2022, then slumped by 100.54% to -$3.0 million in 2023, then tumbled by 1300.0% to -$42.0 million in 2024, then soared by 388.1% to $121.0 million in 2025, then plunged by 519.01% to -$507.0 million in 2026.
• The last three Other financing activities figures came in at -$507.0 million (Q2 2026), $157.0 million (Q1 2026), and $121.0 million (Q4 2025), per Business Quant data.